The Tale of Two TLR7/8 Inhibitors at EULAR 2025: Enpatoran and Afimetoran
Data presented today
The recent EULAR 2025 congress in Barcelona has been a hotbed of innovation, particularly in the challenging landscape of Systemic Lupus Erythematosus (SLE). Among the most anticipated data were presentations on a promising class of molecules: oral Toll-like receptor 7 and 8 (TLR7/8) inhibitors. Two companies, Merck KGaA and Bristol Myers Squibb, presen…
Keep reading with a 7-day free trial
Subscribe to Drug Development Executive to keep reading this post and get 7 days of free access to the full post archives.